S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities

Best Stocks Under $2.00 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.


Cybin stock logo

#1 - Cybin

OTCMKTS:CYBN
Stock Price: $0.46 (+$0.02)
PE Ratio: -1.70
Market Cap: $85.61 million
Average Trading Volume: 2.05 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.13 (1,231.8% Upside)
Cybin, Inc. is an ethical biopharmaceutical company engaged in the development of therapeutics for patients to address a multitude of mental health issues. It is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
BIOLASE stock logo

#2 - BIOLASE

NASDAQ:BIOL
Stock Price: $0.55 (+$0.01)
PE Ratio: -0.15
Market Cap: $4.25 million
Average Trading Volume: 1.12 million shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $9.50 (1,627.3% Upside)
BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.
Leap Therapeutics stock logo

#3 - Leap Therapeutics

NASDAQ:LPTX
Stock Price: $0.64 (-$0.01)
PE Ratio: -1.37
Market Cap: $63.57 million
Average Trading Volume: 1.05 million shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.00 (367.3% Upside)
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Verastem stock logo

#4 - Verastem

NASDAQ:VSTM
Stock Price: $0.70 (+$0.06)
PE Ratio: -1.79
Market Cap: $147.06 million
Average Trading Volume: 1.02 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.00 (614.3% Upside)
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
Surface Oncology stock logo

#5 - Surface Oncology

NASDAQ:SURF
Stock Price: $0.97
PE Ratio: -0.78
Market Cap: $58.82 million
Average Trading Volume: 267,008 shares
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.60 (579.4% Upside)
Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm's pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.
X4 Pharmaceuticals stock logo

#6 - X4 Pharmaceuticals

NASDAQ:XFOR
Stock Price: $1.04
PE Ratio: -0.37
Market Cap: $72.01 million
Average Trading Volume: 830,266 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.86 (559.3% Upside)
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
Pear Therapeutics stock logo

#7 - Pear Therapeutics

NASDAQ:PEAR
Stock Price: $1.17 (+$0.08)
PE Ratio: -5.32
Market Cap: $163.84 million
Average Trading Volume: 230,454 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.25 (434.2% Upside)
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Outlook Therapeutics stock logo

#8 - Outlook Therapeutics

NASDAQ:OTLK
Stock Price: $1.19 (+$0.02)
PE Ratio: -3.61
Market Cap: $305.44 million
Average Trading Volume: 560,666 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.33 (432.2% Upside)
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Xeris Biopharma stock logo

#9 - Xeris Biopharma

NASDAQ:XERS
Stock Price: $1.26 (+$0.04)
PE Ratio: -1.24
Market Cap: $170.77 million
Average Trading Volume: 1.36 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.50 (336.5% Upside)
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Lucid Diagnostics stock logo

#10 - Lucid Diagnostics

NASDAQ:LUCD
Stock Price: $1.31
PE Ratio: -0.89
Market Cap: $50.84 million
Average Trading Volume: 96,378 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.92 (506.9% Upside)
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Vincerx Pharma stock logo

#11 - Vincerx Pharma

NASDAQ:VINC
Stock Price: $1.45 (-$0.06)
PE Ratio: -0.52
Market Cap: $30.73 million
Average Trading Volume: 104,097 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.00 (589.7% Upside)
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Clearside Biomedical stock logo

#12 - Clearside Biomedical

NASDAQ:CLSD
Stock Price: $1.49 (-$0.05)
PE Ratio: -18.63
Market Cap: $89.68 million
Average Trading Volume: 266,077 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.60 (410.1% Upside)
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
Aterian stock logo

#13 - Aterian

NASDAQ:ATER
Stock Price: $1.56 (+$0.04)
PE Ratio: -0.53
Market Cap: $126.16 million
Average Trading Volume: 3.95 million shares
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.30 (175.6% Upside)
Aterian, Inc. is a technology enabled consumer products company. The company's brands include hOme, Vremi, Xtava and RIF6. Its product categories include home and kitchen appliances, kitchenware, environmental appliances, beauty related products and consumer electronics. The company was founded by Yaniv Sarig Zion in 2014 and is headquartered in New York, NY.
Gamida Cell stock logo

#14 - Gamida Cell

NASDAQ:GMDA
Stock Price: $1.67 (+$0.06)
PE Ratio: -1.30
Market Cap: $124.22 million
Average Trading Volume: 469,059 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.80 (666.5% Upside)
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.
Aravive stock logo

#15 - Aravive

NASDAQ:ARAV
Stock Price: $1.82 (+$0.15)
PE Ratio: -0.77
Market Cap: $108.89 million
Average Trading Volume: 100,245 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.20 (350.5% Upside)
Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.
Atreca stock logo

#16 - Atreca

NASDAQ:BCEL
Stock Price: $1.82 (+$0.08)
PE Ratio: -0.66
Market Cap: $71.11 million
Average Trading Volume: 232,646 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.40 (581.3% Upside)
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA.
Chimerix stock logo

#17 - Chimerix

NASDAQ:CMRX
Stock Price: $1.84 (+$0.02)
PE Ratio: 1.05
Market Cap: $161.99 million
Average Trading Volume: 637,029 shares
P/E Ratio: 1.1
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.50 (362.0% Upside)
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Lightning eMotors stock logo

#18 - Lightning eMotors

NYSE:ZEV
Stock Price: $1.01 (+$0.01)
PE Ratio: 2.15
Market Cap: $90.74 million
Average Trading Volume: 2.36 million shares
P/E Ratio: 2.1
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.10 (603.0% Upside)
Lightning eMotors, Inc. designs, manufactures, and sells zero-emission commercial fleet vehicles and powertrains to commercial fleets, large enterprises, original equipment manufacturers, and governments in the United States. It offers zero-emission class 3 to 7 battery electric and fuel cell electric vehicles. The company's vehicles comprise cargo and passenger vehicles, school buses, ambulances, shuttle buses, work trucks, city buses, and motorcoaches. It also offers charging systems and charging infrastructure solutions for commercial medium duty vans and motorcoach fleets. The company was founded in 2008 and is headquartered in Loveland, Colorado.
Lineage Cell Therapeutics stock logo

#19 - Lineage Cell Therapeutics

NYSEAMERICAN:LCTX
Stock Price: $1.40
PE Ratio: -4.83
Market Cap: $237.97 million
Average Trading Volume: 333,995 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.40 (285.7% Upside)
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Ca
Taseko Mines stock logo

#20 - Taseko Mines

NYSEAMERICAN:TGB
Stock Price: $1.65 (-$0.18)
PE Ratio: -55.00
Market Cap: $472.71 million
Average Trading Volume: 1.42 million shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.61 (58.4% Upside)
Taseko Mines Ltd. operates as a mining company engaged in the acquisition, development, and operation of mineral deposits. It holds interest in the Gibraltar, Florence Copper, Aley Niobium, Yellowhead, New Prosperity, and Harmony projects. The company was founded on April 15, 1966 and is headquartered in Vancouver, Canada.
Integra Resources stock logo

#21 - Integra Resources

NYSEMKT:ITRG
Stock Price: $0.70 (+$0.01)
PE Ratio: -2.17
Market Cap: $55.48 million
Average Trading Volume: 89,762 shares
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.96 (325.5% Upside)
Integra Resources Corp., a mineral resources company, engages in the acquisition, exploration, and development of mineral properties in the Americas. It primarily focuses on the development of DeLamar project that consists of DeLamar and Florida Mountain gold and silver deposits comprising 790 unpatented lode, placer, and millsite claims, as well as 16 tax parcels covering an area of approximately 8,673 hectares located in the Owyhee County, south western Idaho. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
Passage Bio stock logo

#22 - Passage Bio

NASDAQ:PASG
Stock Price: $1.56 (+$0.07)
PE Ratio: -0.53
Market Cap: $85.10 million
Average Trading Volume: 157,267 shares
Consensus Rating: Buy (7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.33 (626.5% Upside)
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Saipem stock logo

#23 - Saipem

OTCMKTS:SAPMY
Stock Price: $0.30 (-$0.02)
PE Ratio: 0.94
Average Trading Volume: 28,132 shares
P/E Ratio: 0.9
Consensus Rating: Buy (7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.07 (1,256.7% Upside)
Saipem SpA provides integrated basic and detailed onshore engineering, procurement, project management, and construction services mainly to the oil and gas, complex civil and marine infrastructure, and environmental market sectors. It operates through the following business segments: Offshore Engineering and Construction; Onshore Engineering and Construction; Offshore Drilling; and Onshore Drilling. The Offshore Engineering and Construction segment includes platforms, pipelines, subsea field developments, MMO or Maintenance, Modification, and Operations activities, and the execution of large-scale offshore projects. The Onshore Engineering and Construction segment designs and constructs hydrocarbon production facilities, hydrocarbon treatment facilities, and large onshore treatment and transportation systems and facilities. The Offshore Drilling segment consists of a fleet of vessels for deep water, mid-water, high specifications jack-up, and standard jack-up operations. The Onshore Drilling segment comprises a fleet of drilling rigs for wells in Italy and abroad. The company was founded in 1957 and is headquartered in San Donato Milanese, Italy.
Ayr Wellness stock logo

#24 - Ayr Wellness

OTCMKTS:AYRWF
Stock Price: $1.29 (-$0.05)
PE Ratio: -1.54
Market Cap: $89.19 million
Average Trading Volume: 164,265 shares
Consensus Rating: Buy (6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $22.05 (1,609.3% Upside)
Ayr Wellness Inc., a vertically-integrated cannabis multi-state operator, cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. The company's cannabis and cannabis products include concentrates, edibles, and vaporizers. It also provides administrative, consulting, and operations support services to licensed cannabis companies. As of November 1, 2022, Ayr Wellness Inc. operated 52 dispensaries. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.
Taysha Gene Therapies stock logo

#25 - Taysha Gene Therapies

NASDAQ:TSHA
Stock Price: $1.18 (-$0.03)
PE Ratio: -0.29
Market Cap: $73.68 million
Average Trading Volume: 747,474 shares
Consensus Rating: Buy (11 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.73 (809.6% Upside)
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

More Stock Ideas from MarketBeat